Larimar Therapeutics Soars 12.39% on Deerfield Funds Acquisition

On August 5, 2025, Larimar Therapeutics experienced a significant surge in its pre-market trading, rising by 12.39%.

This surge comes after Deerfield funds acquired $10.8 million worth of shares in Larimar Therapeutics. Following this acquisition, Jones Trading adjusted its price target for Larimar Therapeutics, lowering it from $12 to $10, while still maintaining a Buy rating. This move indicates a cautious optimism about the company's future prospects, despite the reduction in the price target.

Larimar Therapeutics has been in the spotlight recently, with various analysts and investors closely monitoring its performance. The company's stock has seen fluctuations, but the recent acquisition by Deerfield funds suggests a renewed interest and confidence in its potential. The lowered price target by Jones Trading could be seen as a strategic adjustment rather than a bearish outlook, as the firm continues to endorse the stock with a Buy rating.